Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Mar 19, 2018 9:41pm
200 Views
Post# 27743772

RE:RE:RE:RE:RE:RE:RE:RE:Message from IR - news tomorrow AM

RE:RE:RE:RE:RE:RE:RE:RE:Message from IR - news tomorrow AM
IR Reply from Wed:
Thank you for your interest and support. Yes, we will receive the results for our phase 2b clinical study of ATB346 next week. We will be putting out a release with these results next week one they are known. 
With good data the next trial will commence shortly. Exciting times indeed.
Many thanks! Christina 

Follow up on that:
Antibe does not have the results, once we receive these results we must press release immediately . 
The Company and the CRO will go through results together early next week and we will get out a press release immediately for all to know.
I hope this clarifies your questions.
Many thanks!
Christina

IR reply today:
Thank you for your continued interest. The Company is on track to get the release out before market open. 
Many thanks, Christina 


Sounds like I'm probably reading too much into it. last week had no knowledge so they can say "Exciting times" now they are using a canned message.

Although if it's halted, why couldn't they give a clue if it's good or bad? no one will have opportuinty to trade before the NR anyway? I'm sure they probably can't but just got me thinking.

Oh well time to forget about all this for 11 hours.
I'm just gonna prepare for the worst, this way it can only go up from here lol.
Good luck all.

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities